Search research articles
Contact Us
Filters
Showing results (151-160 of 161) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
Ayumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
International Journal of Cancer
|
November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study
Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Debashis Sarker, Ruth Plummer, Tim Meyer, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Cancer Research Communications
|
October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Nature Reviews. Clinical Oncology
|
June 2, 2016
Clinical development of new drug-radiotherapy combinations
Ricky A Sharma, Ruth Plummer, Julie K Stock, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine
|
April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 161) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
Ayumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
International Journal of Cancer
|
November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study
Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Debashis Sarker, Ruth Plummer, Tim Meyer, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Cancer Research Communications
|
October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Nature Reviews. Clinical Oncology
|
June 2, 2016
Clinical development of new drug-radiotherapy combinations
Ricky A Sharma, Ruth Plummer, Julie K Stock, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine
|
April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Page
of 17